Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for ...
CDK 4/6 inhibitors, including abemaciclib, offer new treatments for ER+/HER2- advanced breast cancer. Abemaciclib differs in dosing and side effects but shows similar clinical benefits. Its major impact may be in adjuvant therapy, pending MONARCH-E trial results. Biomarker research could identify tumors most responsive to abemaciclib.
Reference News
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for ...
CDK 4/6 inhibitors, including abemaciclib, offer new treatments for ER+/HER2- advanced breast cancer. Abemaciclib differs in dosing and side effects but shows similar clinical benefits. Its major impact may be in adjuvant therapy, pending MONARCH-E trial results. Biomarker research could identify tumors most responsive to abemaciclib.